Breast Cancer Clinical Trials in Columbus, Ohio

19 studies are recruiting for breast cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Local Institution - 0102, Columbus, Ohio
    Locations
    65 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06618287 on ClinicalTrials.gov

  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  3. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    53 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04893109 on ClinicalTrials.gov

  4. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, Columbus, Ohio
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  5. E-Mindfulness Approaches for Living After Breast Cancer

    NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

    Stage
    Phase 3
    Ages
    18 to 50
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    383 in total
    Run by
    NRG Oncology

    See if you can join NCT06748222 on ClinicalTrials.gov

  6. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    65 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT05768139 on ClinicalTrials.gov

  7. Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

    This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion o…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    3 in total
    Run by
    University of Illinois at Chicago

    See if you can join NCT06169371 on ClinicalTrials.gov

  8. A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer

    The goal of this interventional study is to to evaluate the effectiveness and acceptability of a focused upper body massage when offered after radiation treatments to participants diagnosed with breast cancer. Given the prevalence of musculoskeletal complaints during radiation therapy delivery and …

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT07447700 on ClinicalTrials.gov

  9. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center at Olentangy River Road, Columbus, Ohio
    Locations
    203 in total
    Run by
    Celcuity Inc

    See if you can join NCT06757634 on ClinicalTrials.gov

  10. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  11. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Medical Center, Columbus, Ohio
    Locations
    15 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

  12. Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

    Stage
    Not phased
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT04022616 on ClinicalTrials.gov

  13. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  14. Feasibility Study of CBCT for IGRT in Cancer Patients

    Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    James Outpatient Center, Columbus, Ohio
    Locations
    4 in total
    Run by
    Varian, a Siemens Healthineers Company

    See if you can join NCT06681233 on ClinicalTrials.gov

  15. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

  16. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Columbus, Ohio
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  17. Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

    Breast cancer (BC) is the most frequently diagnosed cancer in women. Systemic cancer treatments are an important contributor to dramatic improvements in the long-term survival of women with BC. However, cancer treatment can lead to cognitive impairment and declines in quality of life in women with …

    Stage
    Not phased
    Ages
    45 to 75
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT05984888 on ClinicalTrials.gov

  18. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

  19. IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

    This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT). The primary aim is to determine the 5-year risk of in-breast tumor recurrence. Secondary …

    Stage
    Not phased
    Ages
    65 and older
    Site
    Mount Carmel West Hospital, Columbus, Ohio
    Run by
    Mount Carmel Health System

    See if you can join NCT03536897 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.